SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-20-008165
Filing Date
2020-05-11
Accepted
2020-05-11 09:01:19
Documents
46
Period of Report
2020-03-31

Document Format Files

Seq Description Document Type Size
1 form10-q.htm 10-Q 562526
2 ex31-1.htm EX-31.1 17348
3 ex32-1.htm EX-32.1 6193
  Complete submission text file 0001493152-20-008165.txt   2620584

Data Files

Seq Description Document Type Size
4 XBRL INSTANCE FILE lixt-20200331.xml EX-101.INS 358057
5 XBRL SCHEMA FILE lixt-20200331.xsd EX-101.SCH 47150
6 XBRL CALCULATION FILE lixt-20200331_cal.xml EX-101.CAL 26909
7 XBRL DEFINITION FILE lixt-20200331_def.xml EX-101.DEF 127298
8 XBRL LABEL FILE lixt-20200331_lab.xml EX-101.LAB 270571
9 XBRL PRESENTATION FILE lixt-20200331_pre.xml EX-101.PRE 179372
Mailing Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733
Business Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733 310 203 2902
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Filer) CIK: 0001335105 (see all company filings)

IRS No.: 202903526 | State of Incorp.: DE
Type: 10-Q | Act: 34 | File No.: 000-51476 | Film No.: 20862857
SIC: 2834 Pharmaceutical Preparations